7 completed, 2 not yet recruiting, 2 unknown, 1 terminated. 12 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 7, Not yet recruiting 2, Unknown 2, Terminated 1 |
| Phase 2 | 5 | Completed 2, Not yet recruiting 1, Terminated 1, Unknown 1 |
Follow Psychomotor Disorders: new trials by email Literature Review of Psychomotor Disorders trials Research Report on Psychomotor Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep Ferrous Sulfate, Placebo - ADHD, Sleep Problems | Phase 1 / Phase 2 | Not yet recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 70 | 2027-03-01 | 2026-05-04 |
| Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants NRL-1004 2.5 mg, ZYPREXA IM 10mg, NRL-1004 5.0 mg - Healthy Adult Participants | Phase 1 | Not yet recruiting | Neurelis, Inc. | 24 | 2026-10-16 | 2026-11-06 |
| Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care Dexmedetomidine Hydrochloride - Hyperactive Delirium, Delirium of Mixed Origin | Phase 1 / Phase 2 | Unknown | Bruyère Health Research Institute. | 50 | 2024-01-30 | 2025-04-15 |
| Memesto Wearable Device for Persons With Dementia Memesto - Alzheimer Disease | Phase 1 | Completed | Edgewater Safety Systems, Inc. | 9 | 2022-08-31 | 2024-01-03 |
| Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal Dexmedetomidine, Placebo - Opioid Withdrawal | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 225 | 2020-06-09 | 2026-08-11 |
| Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia Sublingual film containing Dexmedetomidine, Sublingual Placebo Film - Agitation,Psychomotor, Dementia | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 100 | 2019-12-27 | 2026-08-11 |
| Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film - Agitation, Schizophrenia | Phase 1 | Completed | BioXcel Therapeutics Inc | 135 | 2019-05-22 | 2026-08-11 |
| ASSIST: Treatment for Childhood Apraxia of Speech ASSIST - Childhood Apraxia of Speech | Phase 1 | Completed | Temple University | 51 | 2019-04-18 | 2026-05-22 |
| Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101 Zyprexa IM, Zydis, INP105 - Acute Agitation | Phase 1 | Completed | Impel Pharmaceuticals | 38 | 2018-08-05 | 2018-10-04 |
| Evaluating Anodal tDCS Preceding Aphasia Therapy transcranial direct current stimulation - Stroke, Aphasia | Phase 1 / Phase 2 | Terminated | Northwell Health | 15 | 2014-09-01 | 2021-04-05 |
| PiB PET Scanning in Speech and Language Based Dementias C-11 PiB, F-18 FDG - PPA, Primary Progressive Aphasia | Phase 1 | Completed | Mayo Clinic | 168 | 2010-03-01 | 2015-12-22 |
| Study of Depakote for Behavioral and Psychological Symptoms in Dementia Depakote - Dementia | Phase 1 | Unknown | Hearthstone Alzheimer Care | 20 | 2004-03-01 | 2006-08-15 |
Psychomotor Agitation (9) · Apraxias (3) · Dementia (3) · Schizophrenia (3) · Aphasia (2) · Alzheimer Disease (1) · Aphasia, Broca (1) · Aphasia, Primary Progressive (1) · Attention Deficit Disorder with Hyperactivity (1) · Behavior (1) · Behavioral Symptoms (1) · Bipolar Disorder (1) · Communication Disorders (1) · Death (1) · Delirium (1)
Nervous System Diseases (12) · Neurobehavioral Manifestations (12) · Neurologic Manifestations (12) · Pathological Conditions, Signs and Symptoms (12) · Signs and Symptoms (12) · Mental Disorders (11) · Aberrant Motor Behavior in Dementia (9) · Behavior (9) · Dyskinesias (9) · Behavioral Symptoms (8) · Brain Diseases (5) · Central Nervous System Diseases (5) · Neurocognitive Disorders (5) · Schizophrenia Spectrum and Other Psychotic Disorders (3)
Dexmedetomidine (3) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · Insemination, Artificial, Heterologous (1) · Olanzapine (1) · Transcranial Direct Current Stimulation (1) · Valproic Acid (1) · ferrous sulfate (1)
BioXcel Therapeutics Inc (3) · Bruyère Health Research Institute. (1) · Edgewater Safety Systems, Inc. (1) · Hearthstone Alzheimer Care (1) · Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (1) · Impel Pharmaceuticals (1) · Mayo Clinic (1) · Neurelis, Inc. (1) · Northwell Health (1) · Temple University (1)
United States (9) · Australia (1) · Canada (1)
BioXcel MM, MD (3) · Alison E Pritchard, PhD (1) · Edwin Maas, Ph.D. (1) · James Downar, MDCM, MSc (1) · Jeffery T. Banker, MS (1) · Keith A Josephs, M.D. MST, MSc (1) · Mark Vanelli, MD (1) · Niquita Tugiono, MD (1) · Stephen B Shrewsbury, MD (1)
PMID 32609960, PMID 36280451, PMID 40034447
R01DC017768 (1)